Isomorphic Labs

Isomorphic Labs

Isomorphic Labs is building a future where frontier AI can help to unlock deeper scientific insights, faster breakthroughs, and life-changing medicines.

AI / ML

Built from public sources. Run Isomorphic Labs? Claim this page with your @isomorphiclabs.com email.

Overview

In the news · Nov 18, 2026Isomorphic Labs: $5B (€4.5B) Series C, co-led by Greenoaks and Sequoia Capital. The London AI drug discovery company came back to market six months after its Series B. Raised $5BN Series C. Read the funding digest
About

Science driven by AI to design new medicines. Built for pharmaceutical researchers and patients.

Isomorphic Labs combines frontier AI with rigorous science to reimagine drug discovery and design medicines. The company serves pharmaceutical researchers and patients by using predictive and generative AI models to understand biology, navigate chemical space, and solve complex medical problems that were previously intractable.

Problem & Solution

The problem
Drug discovery is slow and complex, with many diseases lacking effective treatments. Even with advances in protein structure prediction, transforming that knowledge into safe, effective medicines requires solving multiple challenging problems simultaneously.
The solution
Isomorphic Labs has built the Isomorphic Labs Drug Design Engine, which uses predictive and generative AI models to help researchers explore biological complexity, navigate vast chemical design space, and anticipate how drug candidates will perform in order to develop innovative medicines across multiple disease areas.

Fact sheet

Industry
AI / ML

Run Isomorphic Labs? Make this page yours.

Claim it with your @isomorphiclabs.com email, fix what we got wrong, and share one clean link with investors and customers.

Claim this page